//www.igerbera.com/journals/jamacardiology en-us Wed, 22 Mar 2023 00:00:00 GMT Wed, 22 Mar 2023 11:44:10 GMT Silverchair jamams@jamanetwork.org support@www.igerbera.com //www.igerbera.com/journals/jamacardiology/fullarticle/2802861 Wed, 22 Mar 2023 00:00:00 GMT In our annual review of JAMA Cardiology, I am pleased to report that 2022 marked another year of steady growth in publishing original science, reviews, and opinion articles covering the areas of cardiology of interest to our readers. We received 2279 manuscripts (Table), including 1832 original science submissions, which is comparable to prepandemic submissions in 2019. Submissions related to the pandemic and its cardiovascular ramifications totaled 118 (7.9% of total submissions), compared with 12.3% in 2021 and 24.7% in 2020. 10.1001/jamacardio.2023.0294 2802861 //www.igerbera.com/journals/jamacardiology/fullarticle/2802860 Wed, 22 Mar 2023 00:00:00 GMT This randomized clinical trial evaluates the superiority of an augmented double wide-area circumferential ablation vs a standard single wide-area circumferential ablation in preventing recurrent atrial arrhythmias in patients with paroxysmal atrial fibrillation. 10.1001/jamacardio.2023.0212 2802860 //www.igerbera.com/journals/jamacardiology/fullarticle/2802859 Wed, 22 Mar 2023 00:00:00 GMT This cross-sectional study evaluates statin use for primary prevention of atherosclerotic cardiovascular disease in the US by 10-year risk and by race and ethnicity. 10.1001/jamacardio.2023.0228 2802859 //www.igerbera.com/journals/jamacardiology/fullarticle/2802858 Wed, 22 Mar 2023 00:00:00 GMT We sincerely thank the 750 peer reviewers who completed manuscript reviews for JAMA Cardiology in 2022. e230142 10.1001/jamacardio.2023.0142 2802858 //www.igerbera.com/journals/jamacardiology/fullarticle/2802687 Wed, 15 Mar 2023 00:00:00 GMT This cross-sectional study evaluates cardiovascular mortality by US state and by race and ethnicity. 10.1001/jamacardio.2023.0112 2802687 //www.igerbera.com/journals/jamacardiology/fullarticle/2802649 Wed, 15 Mar 2023 00:00:00 GMT To the Editor We thank Solomon et al for a substantive and meaningful addition to the literature on the impact of ascending thoracic aortic aneurysm size on adverse outcomes (type A dissection [TAD] and all-cause death), quite consonant with our prior investigations. We would like to mention the following caveats in the interpretation of this study. 10.1001/jamacardio.2023.0153 2802649 //www.igerbera.com/journals/jamacardiology/fullarticle/2802648 Wed, 15 Mar 2023 00:00:00 GMT In Reply We appreciate the thoughtful comments of Zafar and Elefteriades, whose work we admire, on our study. Below are replies to their comments. 10.1001/jamacardio.2023.0156 2802648

map